Does Semaglutide Reduce Appetite — and How Does It Work?

You're not imagining it: the food noise really does go quiet

A lot of people starting Wegovy expect to feel less hungry in the way they might after a large meal. What catches many of them off guard is something subtler: the constant low-level thinking about food (what's in the fridge, what's for dinner, whether there's anything in the cupboard) simply fades. This is sometimes called "food noise", and it is one of the most consistently reported changes people describe. Our page on whether Wegovy reduces food noise explores this experience in more detail.

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone the gut releases after eating, and one of its jobs is to signal the hypothalamus (the part of the brain that regulates hunger) that food has arrived. Semaglutide mimics this hormone and sustains its effect far longer than the natural version does. The result is a persistent dampening of appetite signals rather than a brief post-meal sense of fullness. There is also a slowing of how quickly food leaves the stomach, which means the physical feeling of fullness lasts longer after eating. These two mechanisms work together, and together they explain why the appetite reduction feels qualitatively different from simply "not being as hungry".

It is worth gently setting aside a common misconception here: some people assume semaglutide works mainly by causing nausea, so they feel too unwell to eat much. Nausea can occur, especially in the early weeks, but it is a side effect the prescribing schedule is designed to minimise, not the reason the medicine reduces appetite. The appetite effect and the nausea are separate things, and the appetite effect persists even in people who experience little or no nausea at all.

When the appetite reduction actually starts, and what affects it

Appetite changes are often noticeable within the first week or two, even at the lowest starting dose. However, the strength of the effect tends to build as the dose increases, which is why the prescribing schedule moves through stages rather than starting at the full maintenance level. The timeline for semaglutide appetite suppression varies between individuals, and some people find the change is more pronounced after each dose step.

Several things can influence how the effect feels day to day. Eating high-fat or very rich foods can intensify nausea without meaningfully increasing satiety, which is why what you eat on Wegovy matters more than many people initially expect. Dehydration can also mask true hunger signals, making it harder to read your appetite accurately. And some people find that caffeine (specifically in large amounts) affects how their stomach feels during treatment; our page on caffeine and Wegovy covers that in context.

Protein intake deserves particular attention. When appetite falls significantly, there is a risk of eating too little overall and (within that) not enough protein to support muscle mass. A prescriber or dietitian can help you work out a practical approach to this. The appetite reduction is a tool; the diet still needs thought.

Does Wegovy just reduce appetite, or is there more to how it works?

It is a fair question, and one that comes up often. The short answer is that appetite reduction is the central mechanism for weight loss, but semaglutide does more than one thing. In the STEP 1 trial published in the New England Journal of Medicine, adults taking semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of body weight over 68 weeks, a result that reflects sustained appetite reduction combined with the dietary and activity changes participants made.

Beyond appetite, semaglutide also affects how rewarding food feels to some people, which may reduce the pull of highly palatable foods independently of physical hunger. It improves blood-sugar regulation, which can smooth out the energy dips that often drive snacking. And for some people, reduced cravings for alcohol or ultra-processed foods have been reported, though research in those areas is still developing. Our broader page on semaglutide and appetite covers the full picture of these mechanisms.

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. Suitability is assessed individually at consultation, our Wegovy page has a full overview of who it is licensed for and how the process works. For those considering cost, Wegovy cost in the UK sets out what private treatment typically involves and what any legitimate price should include.

If you have questions about whether semaglutide's appetite effects are likely to suit your situation, speaking to our prescribers is the straightforward next step. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber, and there is no charge for the initial assessment.